ファースト・トラックス・バイオセラピューティクス
First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -1.45 | $0 | -$33M |
| 2025 Q1 | -1.36 | $0 | -$45M |